Research for Plasma Biomarkers Associated With Fatigue in Thrombocytopenic Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

280 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-03-26

Study Completion Date

2028-06-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Thrombocytopenia is a clinical problem defined by a platelet count lower than 150×10⁹/L. It can be linked to various pathologies of central origin, such as decreased platelet production in the bone marrow, or peripheral origin with increased platelet destruction through autoimmune mechanisms, increased splenic sequestration, or excessive platelet consumption. Significant fatigue is often reported in association with thrombocytopenia, but its underlying pathophysiology remains unclear. One hypothesis is the role played by neurotrophic factors contained in platelets and released into the circulation following their activation, in particular the Brain-Derived Neurotrophic Factor (BDNF), which promotes the survival, growth, differentiation, and plasticity of neurons in both the central and peripheral nervous systems. Consequently, BDNF plays a key role in long-term memory, intellectual abilities, and neuroprotection.

In this context, this project aims to confirm whether platelet-origin neurotrophic biomarkers could explain the fatigue experienced by thrombocytopenic patients and whether it depends on the etiology of the thrombocytopenia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Idiopathic Chronic Thrombocytopenia of Undetermined Significance : Pathogenesis and Biomarker

NCT04003220

Thrombocytopenia Purpura, Thrombocytopenic Myelodysplastic Syndromes

UNKNOWN

Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias.

NCT01933035

Immune Thrombocytopenia Chemotherapy Induced Thrombocytopenia Myelodysplasia +1 more

COMPLETED

Ultrasound to Detect Splenomegally in Patients With Isolated Thrombocytopenia

NCT07182760

Primary Immune Thrombocytopenic Purpura Amegakaryocytic Aplasia Unilineage Myelodysplastic Syndrome ( Megakaryocyte Dysplasia) +2 more

NOT_YET_RECRUITING

Diagnostic of Chronic Thrombocytopenia

NCT04071496

Congenital Thrombocytopenia Chronic Idiopathic Thrombocytopenic Purpura

COMPLETED

Study of Immune Thrombocytopenia Pathogenesis:

NCT02042560

Primary Immune Thrombocytopenia (ITP)

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Thrombocytopenia is defined as a platelet count below 150×109/L. The mechanisms leading to thrombocytopenia are multiple, and may be linked to :

* reduced platelet production in the bone marrow;
* increased destruction of peripheral platelets;
* increased splenic sequestration. In the event of a vascular breach, platelets contribute to hemostasis by sealing the lesion, thereby stopping bleeding. In thrombocytopenic patients, the best-known clinical signs are excessive mucocutaneous bleeding. Patients with severe thrombocytopenia (\< 20×109 /L) may be at risk of life-threatening bleeding (cerebral bleeding).

In the case of autoimmune thrombocytopenia, cognitive disorders have been reported, detected by appropriate questionnaires, the pathophysiological mechanism of which remains unclear. In a study of 1871 patients with thrombocytopenia, 39% of patients in the UK and 22% in the USA reported severe asthenia. Asthenia appears to be related to thrombocytopenia, but the mechanism has not been identified either. Asthenia is a recognized symptom in other autoimmune pathologies, such as primary biliary cirrhosis (autoimmune liver disease), in which asthenia has been shown to be mainly associated with autonomic nervous system dysfunction.

While thrombocytopenia is primarily associated with bleeding risk, at least half of thrombocytopenic patients report fatigue and impaired mental and emotional health and social functioning, even though anemia is corrected and the association with autoimmune disease does not explain fatigue in all thrombocytopenic patients.

The hypothesis is that thrombocytopenia is associated with a decrease in circulating neurotrophic factor levels through reduced platelet granule secretion, which may explain the fatigue.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Thrombopenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients

Minor patients (8 years of age or older) and adult patients seen consecutively in a hematology consultation as part of the follow-up of their thrombocytopenia.

Group Type OTHER

blood sampling

Intervention Type BIOLOGICAL

3 blood tubes will be taken during a standard check-up

self-administrated questionaires

Intervention Type OTHER

4 self administrated questionaires and scales at the inclusion

Control group

Control group (n=80) who will consist of healthy adult subjects (without pathology and without treatment) matched by age (± 5 years) and sex to adult patients included in the study given the possible influence of age and sex on circulating BDNF concentrations

Group Type OTHER

blood sampling

Intervention Type BIOLOGICAL

3 blood tubes will be taken during a standard check-up

self-administrated questionaires

Intervention Type OTHER

4 self administrated questionaires and scales at the inclusion

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

blood sampling

3 blood tubes will be taken during a standard check-up

Intervention Type BIOLOGICAL

self-administrated questionaires

4 self administrated questionaires and scales at the inclusion

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with constitutional or autoimmune (chronic or persistent ITP with last treatment administration ≥ 3 weeks) thrombocytopenia (platelet count \< 150×109/L) already diagnosed
* patient not being treated and not receiving serotonin reuptake inhibitor (SSRI) or norepinephrine (SNRI) or antithrombotic treatments (antiplatelet or anticoagulant) in the 10 days prior to inclusion
* affiliation to social security (beneficiary or assignee)
* patient followed in consultation in one of the recruiting haematology departments
* Patient (or parent) having received a detailed explanation of the research project and having consent by signing the consent form before any research-specific procedure

* Age- (± 5 years) and sex-matched healthy adult controls
* Non-thrombocytopenic patients and not receiving antithrombotic, SNRI or SSRI therapy or if applicable, last treatment ≥ 10 days
* affiliation to social security (beneficiary or assignee)
* adults who received a detailed explanation of the research project and having consent by signing the consent form before any research-specific procedure

* Adult patients under legal protection (guardianship or curatorship) Thrombocytopenic patients treated with antithrombotics, serotonin reuptake inhibitors (SSRIs) or noradrenaline reuptake inhibitors (SNRIs)
* Minor patients weighing less than 20 kg

* Healthy adult volunteers under legal protection (guardianship, curatorship or safeguard of justice).
* Pregnant women

Minimum Eligible Age

8 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes